BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33553672)

  • 1.
    Sue S; Sasaki T; Kaneko H; Irie K; Kondo M; Maeda S
    JGH Open; 2021 Feb; 5(2):307-311. PubMed ID: 33553672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Vonoprazan, Clarithromycin, and Metronidazole Regimen as Helicobacter pylori Eradication Therapy for Patients with Penicillin Allergy in Light of Clarithromycin Resistance.
    Adachi K; Kato S; Koshino A; Nagao K; Sugiyama T; Yoshimine T; Yamaguchi Y; Izawa S; Ohashi W; Ebi M; Funaki Y; Ogasawara N; Sasaki M; Kasugai K
    Intern Med; 2023 Aug; 62(16):2301-2306. PubMed ID: 36631092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-Line
    Sue S; Suzuki N; Shibata W; Sasaki T; Yamada H; Kaneko H; Tamura T; Ishii T; Kondo M; Maeda S
    Gastroenterol Res Pract; 2017; 2017():2019802. PubMed ID: 29181022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective Study of Vonoprazan-Based First-Line Triple Therapy with Amoxicillin and Metronidazole for Clarithromycin-Resistant
    Sue S; Suzuki Y; Sasaki T; Kaneko H; Irie K; Komatsu K; Maeda S
    J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin.
    Ono S; Kato M; Nakagawa S; Mabe K; Sakamoto N
    Helicobacter; 2017 Jun; 22(3):. PubMed ID: 28098408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori.
    Saito Y; Konno K; Sato M; Nakano M; Kato Y; Saito H; Serizawa H
    Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30669474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
    Sue S; Shibata W; Sasaki T; Kaneko H; Irie K; Kondo M; Maeda S
    J Gastroenterol Hepatol; 2019 Apr; 34(4):686-692. PubMed ID: 30151994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori.
    Furuta T; Yamade M; Kagami T; Uotani T; Suzuki T; Higuchi T; Tani S; Hamaya Y; Iwaizumi M; Miyajima H; Umemura K; Osawa S; Sugimoto K
    Digestion; 2020; 101(6):743-751. PubMed ID: 31434101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic resistance and
    Mori H; Suzuki H; Matsuzaki J; Masaoka T; Kanai T
    United European Gastroenterol J; 2017 Oct; 5(6):796-804. PubMed ID: 29026593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled study on the effects of triple therapy including vonoprazan or rabeprazole for the second-line treatment of
    Hojo M; Asaoka D; Takeda T; Shimada Y; Matsumoto K; Matsumoto K; Yatagai N; Akazawa Y; Ueda K; Ueyama H; Nagahara A
    Therap Adv Gastroenterol; 2020; 13():1756284820966247. PubMed ID: 33240391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful Eradication Therapy for Helicobacter pylori-positive Atrophic Gastritis at the Sixth Attempt: A Case Report.
    Deguchi R; Shiraishi K; Arase Y; Dekiden M; Shimada H; Miyakita H; Ogimi T; Myojin K; Mine T
    Tokai J Exp Clin Med; 2016 Dec; 41(4):233-235. PubMed ID: 27988924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
    Kajihara Y; Shimoyama T; Mizuki I
    Scand J Gastroenterol; 2017 Feb; 52(2):238-241. PubMed ID: 27806639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line triple therapy in failures with vonoprazan-based triple therapy for eradication of
    Mori N; Nishiura Y; Suga D; Moritani I; Yamanaka Y; Ooya Y; Inoue H; Takase K; Hioki M; Shiraki K
    Biomed Rep; 2018 Aug; 9(2):169-174. PubMed ID: 30013779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy.
    Mori H; Suzuki H; Matsuzaki J; Masaoka T; Kanai T
    Digestion; 2020; 101(5):644-650. PubMed ID: 31387107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of vonoprazan combined with different dose amoxicillin on eradication of
    Lin Y; Xu H; Yun J; Yu X; Shi Y; Zhang D
    Ann Transl Med; 2022 Sep; 10(18):987. PubMed ID: 36267745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Vonoprazan in
    Sugimoto M; Yamaoka Y
    Front Pharmacol; 2018; 9():1560. PubMed ID: 30697158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and mechanism of vonoprazan-containing triple therapy in the eradication of
    Zhang Z; Liu F; Ai F; Chen X; Liu R; Zhang C; Fang N; Fu T; Wang X; Tang A
    Front Pharmacol; 2023; 14():1143969. PubMed ID: 37214450
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety comparison of
    Wang Z; Wang F
    Therap Adv Gastroenterol; 2022; 15():17562848221125308. PubMed ID: 36268270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of a new rifabutin-based triple therapy with vonoprazan for refractory Helicobacter pylori infection: A prospective single-arm study.
    Hirata Y; Yamada A; Niikura R; Shichijo S; Hayakawa Y; Koike K
    Helicobacter; 2020 Oct; 25(5):e12719. PubMed ID: 32602161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of
    Liu L; Nahata MC
    Antibiotics (Basel); 2023 Apr; 12(4):. PubMed ID: 37107099
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.